An interventional study of Integrated Snoezelen-Aromatherapy-Personal Item Therapy in Dementia and Agitation in Dementia, Including Alzheimer's Disease, sponsored by Mostafa Shaban. Enrolling by invitation at 1 site in Egypt. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-02-06.
Sponsored by Mostafa Shaban · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the effectiveness of integrating Snoezelen methods with aromatherapy and personal items in reducing agitation in Arab elderly individuals with dementia. The main questions it aims to answer are:
Does the combination of Snoezelen methods, aromatherapy, and the use of personal items significantly reduce agitation in elderly Arab patients with dementia compared to standard care practices? How do patients and caregivers perceive the impact of this integrated approach on the overall well-being and quality of life of the patients?
Participants in this study will:
Engage in sessions utilizing Snoezelen methods, a multi-sensory environment designed to deliver stimuli to various senses.
Receive aromatherapy treatments with selected scents known for their calming properties.
Be provided with personal items that are familiar and meaningful to them, to create a sense of comfort and security.
This clinical trial is centered on a novel approach to dementia care, specifically targeting the Arab elderly demographic. It uniquely combines three elements - Snoezelen therapy, aromatherapy, and the use of personal items - to address agitation, a common and challenging symptom in dementia patients.
Snoezelen Therapy Implementation:
Custom-designed Snoezelen rooms will be used, equipped with lights, colors, sounds, and textures to stimulate senses in a controlled manner.
Sessions will be tailored to individual patient needs and preferences, monitored by trained staff.
Aromatherapy Application:
Selection of aromas will be based on their known calming properties, with a focus on cultural relevance and acceptability in the Arab elderly population.
The method of delivery and duration of each aromatherapy session will be standardized to ensure consistency across the study.
Incorporation of Personal Items:
Patients will be encouraged to select personal items that hold significant emotional value or are tied to pleasant memories.
These items will be integrated into the therapy sessions to provide a sense of familiarity and emotional comfort.
Data Collection and Analysis:
Quantitative data on agitation levels will be gathered using established agitation scales, both pre- and post-intervention.
The study aims to provide a comprehensive evaluation of how this integrated approach can influence agitation in dementia, considering both statistical effectiveness and personal experiences. The outcome will contribute valuable insights into dementia care practices, particularly for the Arab elderly population, and may offer a template for culturally sensitive dementia care.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
This study's planned enrollment of 80 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Browse Dementia studies →Mostafa Shaban is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the study \"Enhancing Calm in Arab Elderly with Dementia: Integrating Snoezelen Methods with Aromatherapy and Personal Items to Reduce Agitation\", here are the suggested Inclusion and Exclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
Participants receiving the integrated approach of Snoezelen therapy, aromatherapy, and the use of personal items.
Behavioral: Integrated Snoezelen-Aromatherapy-Personal Item Therapy
Participants receiving standard care practices for dementia and agitation without the integrated approach.
Intervention Description: This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation. Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals. Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized
Reduction in Agitation Levels
The primary outcome measure is the reduction in agitation levels among the Arab elderly with dementia participating in the study. This will be quantitatively assessed using a validated agitation scale, such as the Cohen-Mansfield Agitation Inventory (CMAI) or a similar tool appropriate for dementia patients.
Time frame: 4 weeks
Started Jan 2024 (actual). Primary completion is estimated for Feb 2024, 0 months after the start.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 0 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mostafa Shaban